How can the above listed companies justify NOT attending industry trade shows such as NACDS?
Acella
- Thread starter Anonymous
- Start date
-
- Tags
- None
Quite easy. They are a waste of time and unnecessary.
IMO the aforementioned companies do not attend the various industry events because everyone from the owners down to the business development personnel are involved in multiple ventures with the people attending these events. If their employment contract allows for "moonlighting", then there is nothing wrong with consulting for other companies. I however would never allow my full-time employees to work on behalf of another company in the same industry.
Lol...they used to attend regularly. I wonder if they are having financial issues? Can only sell so many prenatal vitamins these days.
That company always seems to be having financial problems. Spending too much on attorneys.
They love to spend money in court where generally speaking no one wins. If this company would spend that money on developing Rx products they might be in a better position?
Some crazy chatter in the home office...some people aren’t as bright as they think they are
People talk too loud, know too many things, gossip too much and assume too much
Kiddie City likes to talk about eating disorders, relationships, weights, favorites maybe if they worked we would have more results.
Acella, Avion, Acrogen etc are all owned and run by the same VERY SHADY group......Art Deas,, Mark Pugh ............
A Pharma Company Raised the Price of a Daily Vitamin by 800 Percent
Jennings Brown
12/12/17 12:15pm
Filed to: BIG PHARMA
18.1K
847
Photo: Getty
If you would like to take niacin, a B vitamin that is believed to lower cholesterol and the chance of having a heart attack, you could buy a month’s supply online for about $5. Or you could get a prescription for a bottle of virtually the same pills for almost $300, thanks to a pharmaceutical company using price gouging tactics similar to those of Pharma Bro Marin Shkrelli, according to a report from the Financial Times.
Since biotech felon Shkrelli became mired in controversy after his company raised the price of a drug used by cancer and HIV patients by 5,500 percent, there have been fewer instances of grotesque buy-and-rise deals in the world of Big Pharma. But some under-the-radar firms are still acquiring patents and immediately gouging.
Avondale Pharmaceuticals recently acquired Niacor, a prescription version of niacin, and increased the price of a bottle of 100 tablets from $32.46 to $295, FT reports. The company was formed in August and has no online presence, but state records show that it is based in Alabama. Acrogen Pharmaceuticals, which is the registered agent for Avondale, did not respond to a request by Gizmodo for comment.
FT was also not able to get a comment from anyone associated with Avondale or Acrogen, which was started last year by Mark Pugh, an executive behind a several pharmaceutical companies (all of which seem to start with the letter “A”: Alora, Acella, Avion, Alliant). The financial news outlet was able to confirm the price increase through the drug price databases of Elsevier and Truven Health Analytics.
While niacin is available over the counter, some healthcare professionals prefer prescription versions that have US Food and Drug Administration approval. There are other prescription versions of niacin, but Niacor is the only one that isn’t extended-release, according to FT. Last year, there were about 19,000 Niacor prescriptions in the US. Avondale seems to have been established just to acquire Niacor and the respiratory drug SSKI from Upsher Smith, a Japan pharmaceutical company.
“This is the latest example of an inefficient US market where the consumer, payer, and doctor don’t have all of the information available to make a financially sound choice,” Michael Rae, CEO of Rx Savings, a company that builds software to find lower price on drugs, told FT. “They are caught in a web of inefficiency and are being taken advantage of.”
Since price increases are not usually public, doctors who have been prescribing Niacor likely do not know about the steep price increase.
[Financial Times]
What great business practices. These companies are just a web...Alora, Acella, Acrogen, Avion, Avondale, Alliant, etc.